Anti-CTLA-4 hopeful cleared for sprint to market after early data show rare tumour shrinkage in hard-to-treat patients.

Investigators presented initial results from a phase 3 trial of adjuvant durvalumab plus tremelimumab for resected primary renal cell carcinoma (RCC).

Replimune Group (($REPL)) announced an update on their ongoing clinical study. Replimune Group is conducting a pivotal Phase 3 clinical study ...

((HK:9926)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and ...